Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe
Year: 2010
Type: review
Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) isa major cause of healthcare- and community-associated infections worldwide. Within the healthcare setting alone, MRSA infections are estimated to affect more than 150,000 patients annually in the European Union (EU), resulting in attributable extra in-hospital costs of EUR 380 million for EU healthcare systems. Pan-European surveillance data on bloodstream infections show marked variability among EU Member States in the proportion of S. aureus that are methicillin-resistant, ranging from less than 1% to more than 50%. In the past five years, the MRSA bacteraemia rates have decreased significantly in 10 EU countries with higher endemic rates of MRSA infections. In addition to healthcare-associated infections, new MRSA strains have recently emerged as community and livestock-associated human pathogens in most EU Member States. The prevention and control of MRSA have therefore been identified as public health priorities in the EU. In this review, we describe the current burden of MRSA infections in healthcare and community settings across Europe and outline the main threats caused by recent changes in the epidemiology of MRSA. Thereby, we aim at identifying unmet needs of surveillance, prevention and control of MRSA in Europe.
Source: Eurosurveillance
Institutions: University Hospital Münster, Health Protection Agency, University of Twente, University of Geneva, University Hospital of Geneva, Amphia Ziekenhuis, Amsterdam UMC Location Vrije Universiteit Amsterdam, Robert Koch Institute, Statens Serum Institut, Université Libre de Bruxelles, Erasmus Hospital, European Centre for Disease Prevention and Control, Università Cattolica del Sacro Cuore
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W1857740374
